Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch

Maia Kayal; Elizabeth A. Spencer; Matthew Smyth; Laura Raffals; Taha Qazi; Parakkal Deepak; Poonam Beniwal-Patel; Shannon Chang; Peter Higgins; Raymond K. Cross; Chelsea Anderson; Millie Long; Hans H. Herfarth; Marla C. Dubinsky; Edward L. Barnes

doi:10.1093/ibd/izae164

Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch

Maia Kayal
, Elizabeth A. Spencer
, Matthew Smyth
, Laura Raffals
, Taha Qazi
, Parakkal Deepak
, Poonam Beniwal-Patel
, Shannon Chang
, Peter Higgins
, Raymond K. Cross
, Chelsea Anderson
, Millie Long
, Hans H. Herfarth
, Marla C. Dubinsky
, Edward L. Barnes

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.

Original language	English
Pages (from-to)	878-881
Number of pages	4
Journal	Inflammatory bowel diseases
Volume	31
Issue number	3
DOIs	https://doi.org/10.1093/ibd/izae164
State	Published - Mar 1 2025

Access to Document

10.1093/ibd/izae164

Cite this

Kayal, M., Spencer, E. A., Smyth, M., Raffals, L., Qazi, T., Deepak, P., Beniwal-Patel, P., Chang, S., Higgins, P., Cross, R. K., Anderson, C., Long, M., Herfarth, H. H., Dubinsky, M. C., & Barnes, E. L. (2025). Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch. Inflammatory bowel diseases, 31(3), 878-881. https://doi.org/10.1093/ibd/izae164

@article{5817c7a44ce14f93b80ccb5dc105ff1c,

title = "Risankizumab Is Effective for The Management of Crohn{\textquoteright}s Disease of the Pouch",

abstract = "In this prospective, multicenter observational study of highly refractory patients with Crohn{\textquoteright}s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50\% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8\% at 12 weeks.",

author = "Maia Kayal and Spencer, \{Elizabeth A.\} and Matthew Smyth and Laura Raffals and Taha Qazi and Parakkal Deepak and Poonam Beniwal-Patel and Shannon Chang and Peter Higgins and Cross, \{Raymond K.\} and Chelsea Anderson and Millie Long and Herfarth, \{Hans H.\} and Dubinsky, \{Marla C.\} and Barnes, \{Edward L.\}",

year = "2025",

month = mar,

day = "1",

doi = "10.1093/ibd/izae164",

language = "English",

volume = "31",

pages = "878--881",

journal = "Inflammatory bowel diseases",

issn = "1078-0998",

number = "3",

}

TY - JOUR

T1 - Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch

AU - Kayal, Maia

AU - Spencer, Elizabeth A.

AU - Smyth, Matthew

AU - Raffals, Laura

AU - Qazi, Taha

AU - Deepak, Parakkal

AU - Beniwal-Patel, Poonam

AU - Chang, Shannon

AU - Higgins, Peter

AU - Cross, Raymond K.

AU - Anderson, Chelsea

AU - Long, Millie

AU - Herfarth, Hans H.

AU - Dubinsky, Marla C.

AU - Barnes, Edward L.

PY - 2025/3/1

Y1 - 2025/3/1

N2 - In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.

AB - In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.

UR - https://www.scopus.com/pages/publications/86000289643

U2 - 10.1093/ibd/izae164

DO - 10.1093/ibd/izae164

M3 - Article

C2 - 39038228

AN - SCOPUS:86000289643

SN - 1078-0998

VL - 31

SP - 878

EP - 881

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 3

ER -

Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch

Abstract

Access to Document

Other files and links

Fingerprint

Cite this